Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
THE RELATIONSHIP BETWEEN METABOLIC SYNDROME AND ARTERIAL
HYPERTENSION: PATHOGENESIS, DIAGNOSIS, AND TREATMENT
APPROACHES
Mavlonov Namoz Xalimovich
Associate Professor, Department of Internal Medicine in Family Medicine, Bukhara State
Medical Institute named after Abu Ali Ibn Sina, PhD
ORCID ID: 0000-0003-0348-9860
Abstract:
Metabolic syndrome and arterial hypertension are currently among the most
serious and pressing issues in global healthcare. These two conditions frequently coexist and
significantly increase the risk of cardiovascular diseases, decreased insulin sensitivity, and
the development of type 2 diabetes. This article explores the interrelation between these
conditions, their pathophysiological mechanisms, diagnostic criteria, and modern treatment
approaches.
Keywords:
Cardiovascular diseases, metabolic syndrome, arterial hypertension, insulin
resistance, treatment.
Introduction.
Metabolic syndrome (MS) is a cluster of multiple metabolic disorders occurring
simultaneously. It typically includes abdominal obesity, elevated blood glucose levels, lipid
metabolism disorders (dyslipidemia), and arterial hypertension. Metabolic syndrome is
recognized as a major risk factor for serious complications such as cardiovascular diseases,
stroke, and type 2 diabetes. Notably, arterial hypertension is one of the core components of
this syndrome and requires careful medical monitoring and management.
THE CONCEPT OF METABOLIC SYNDROME AND ITS COMPONENTS
Arterial hypertension is considered one of the key and most dangerous components of
metabolic syndrome. According to research, 50–70% of patients with metabolic syndrome
have elevated blood pressure levels. This condition leads to increased cardiovascular load,
decreased elasticity of the aorta and other blood vessels, and a significantly heightened risk
of myocardial infarction and stroke. The development of hypertension in the context of
metabolic syndrome is driven by several major factors:
Insulin resistance
– the div's cells become less responsive to insulin, resulting in
endothelial dysfunction. The endothelium (the inner lining of blood vessels) produces less
nitric oxide (NO), which is crucial for vasodilation. As a result, blood vessels remain
constricted, vascular tone increases, and blood pressure rises.
Hyperinsulinemia
– excess insulin levels in the blood promote increased reabsorption of
sodium in the kidneys, leading to fluid retention, increased blood volume, and elevated
blood pressure. Additionally, elevated insulin activates the sympathetic nervous system,
causing increased heart rate and vasoconstriction.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Adipokines and inflammatory markers
– obesity-associated substances such as leptin,
resistin, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) contribute to chronic
inflammation within the circulatory system, exacerbating hypertension. At the same time,
levels of adiponectin — a protective molecule — are reduced, diminishing vascular
protection and regulation.
Renin-angiotensin-aldosterone system (RAAS) activity
– in metabolic syndrome, the
RAAS becomes overactive, leading to vasoconstriction and sodium/water retention via
aldosterone, which plays a central role in the pathogenesis of hypertension.
In metabolic syndrome, arterial hypertension typically develops insidiously, often without
noticeable symptoms, and may remain undiagnosed for a long time. Therefore, it is essential
to regularly monitor blood pressure in all patients with metabolic syndrome, to ensure early
diagnosis and timely preventive measures.
The International Diabetes Federation (IDF) and the U.S. National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) define metabolic syndrome based on
the following key criteria:
Abdominal obesity (waist circumference: >94 cm in men, >80 cm in women)
Triglycerides: >1.7 mmol/L
HDL cholesterol: <1.03 mmol/L in men, <1.29 mmol/L in women
Blood pressure: ≥130/85 mmHg
Fasting glucose: ≥5.6 mmol/L
If a patient meets at least three of the above criteria, a diagnosis of metabolic syndrome is
established.
PATHOGENESIS
The main pathogenic links between metabolic syndrome and hypertension can be
summarized as follows:
Mechanism
Description
Insulin resistance
Leads to endothelial dysfunction and reduced nitric oxide (NO)
production, causing vasoconstriction.
Hormonal imbalance
Disruption in the balance between leptin and adiponectin
contributes to vascular changes.
Chronic inflammation Increased markers such as CRP and IL-6 damage blood vessel
walls.
Hyperactive
sympathetic system
Enhances cardiac output and elevates blood pressure.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
DIAGNOSIS
The following assessments are crucial in diagnosing metabolic syndrome:
Anthropometric measurements (e.g., waist circumference)
Blood pressure monitoring
Laboratory tests:
Fasting blood glucose level
Lipid profile (triglycerides, HDL, LDL)
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
TREATMENT APPROACHES
Management of metabolic syndrome and arterial hypertension requires a comprehensive,
multi-pronged approach:
A. Lifestyle modification:
Healthy diet (low in fats and sugars)
Regular physical activity (at least 150 minutes of aerobic exercise per week)
Weight loss in overweight/obese individuals
B. Pharmacotherapy:
Blood pressure control: ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics
Glycemic control: metformin, GLP-1 receptor agonists
Dyslipidemia management: statins
Antiplatelet therapy: aspirin (in patients with high cardiovascular risk)
Conclusion:
Metabolic syndrome and arterial hypertension are interrelated conditions that represent
pressing challenges for global healthcare systems. A deep understanding of their
pathogenesis, timely diagnosis, and implementation of comprehensive treatment strategies
are essential in reducing the risk of cardiovascular diseases. Promoting a healthy lifestyle
among the general population plays a crucial role in the prevention of these conditions.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
References
1.
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K.
A., ... & Smith, S. C. (2009). Harmonizing the metabolic syndrome: a joint interim statement
of the International Diabetes Federation Task Force on Epidemiology and Prevention.
Circulation, 120
(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
2.
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004).
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood
Institute/American Heart Association conference.
Circulation, 109
(3), 433–438.
https://doi.org/10.1161/01.CIR.0000111245.75752.C6
3.
Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human
disease.
Diabetes, 37
(12), 1595–1607. https://doi.org/10.2337/diab.37.12.1595
4.
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., ... &
Ruilope, L. M. (2013). 2013 ESH/ESC Guidelines for the management of arterial
hypertension.
Journal
of
Hypertension,
31
(7),
1281–1357.
https://doi.org/10.1097/01.hjh.0000431740.32696.cc
5.
Kaur, J. (2014). A comprehensive review on metabolic syndrome.
Cardiology
Research and Practice
, 2014, 943162. https://doi.org/10.1155/2014/943162
6.
DeFronzo, R. A., & Ferrannini, E. (1991). Insulin resistance: a multifaceted
syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic
cardiovascular
disease.
Diabetes
Care,
14
(3),
173–194.
https://doi.org/10.2337/diacare.14.3.173
7.
Esser, N., Paquot, N., & Scheen, A. J. (2015). Anti-inflammatory agents to treat or
prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Expert Opinion on
Investigational Drugs, 24
(3), 283–307. https://doi.org/10.1517/13543784.2015.985290
8.
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey Jr, D. E., Collins, K. J.,
Dennison Himmelfarb, C., ... & Wright Jr, J. T. (2018). 2017 ACC/AHA guideline for the
prevention, detection, evaluation, and management of high blood pressure in adults.
Journal
of
the
American
College
of
Cardiology,
71
(19),
e127–e248.
https://doi.org/10.1016/j.jacc.2017.11.006
